Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,17
KB0,53
PKN8787,13,94
Msft1,79
Nokia5,1085,1880,00
IBM-1,94
Daimler AG57,3757,39-2,35
PFE-0,08
21.7.2018 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 20.7.2018
Ultragenyx Pharm (NASDAQ Cons)
Závěr k 20.7.2018 Změna (%) Změna (USD) Objem obchodů (ks)
82,90 -1,19 -1,00 719 089
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.7.2018
Popis společnosti
Obecné informace
Název společnostiUltragenyx Pharmaceutical Inc
TickerRARE
Kmenové akcie:Ordinary Shares
RICRARE.O
ISINUS90400D1081
Prioritní akcieConv. Pref. Shrs
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 520
Akcie v oběhu k 3.5.2018 49 772 297
MěnaUSD
Kontaktní informace
Ulice60 Leveroni Ct
MěstoNOVATO
PSČ94949-5746
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon14 154 838 800
Fax14154838810

Business Summary: Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.
Financial Summary: BRIEF: For the three months ended 31 March 2018, Ultragenyx Pharmaceutical Inc revenues increased from $0K to $10.7M. Net income totaled $30.3M vs. loss of $68.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net Income reflects Interest Income increase of 61% to $1.7M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.63 to $0.63.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 22.7.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardDaniel Welch60
President, Chief Executive Officer, DirectorEmil Kakkis57
Chief Financial Officer, Executive Vice PresidentShalini Sharp43
Executive Vice President, General CounselKarah Parschauer4020.6.201620.6.2016
Chief Technical Operations Officer, Executive Vice PresidentDennis Huang534.6.2015
Chief Business Officer, Executive Vice PresidentThomas Kassberg57
Chief Quality Operations Officer and Executive Vice President Analytical Sciences and ResearchJohn Pinion5213.7.2015
Chief Medical Officer and Executive Vice PresidentCamille Bedrosian65